[New antibacterial agents on the market and in the pipeline].
Freiburg, Germany. In Internist (berl), Nov 2015
New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin).
mRNA metabolism and neuronal disease.
Würzburg, Germany. In Febs Lett, Jul 2015
Here we discuss three prominent genetic diseases that fall into this category, namely spinal muscular atrophy (SMA), retinitis pigmentosa (RP) and X-linked syndromic mental retardation (XLMR).
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
Hayward, United States. In J Med Chem, 2014
This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), distinguished by its high activity against Gram-positive pathogens coupled with markedly reduced potential for myelosuppression and MAOI.
X-linked mental deficiency.
Lyon, France. In Handb Clin Neurol, 2012
X-linked mental retardation (XLMR) includes more than 200 syndromes and 80 genes identified to date.